| Identification | Back Directory | [Name]
Mezagitamab | [CAS]
2227490-52-8 | [Synonyms]
Mezagitamab
Mezagitamab (anti-CD38)
Research Grade Mezagitamab (DHD80803) |
| Hazard Information | Back Directory | [Uses]
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP)[1][2][3]. | [in vivo]
Mezagitamab (0.03-100 mg/kg, iv, once or twice a week for 4-13 weeks) leads to the depletion of NK cells, B cells and T cells in cynomolgus monkey models[4].
Mezagitamab (3 mg/kg, iv,once weekly for 8 weeks) prevents collagen-induced arthritis in cynomolgus monkey models[4]. | Animal Model: | Cynomolgus monkey models[4] | | Dosage: | 0.03-100 mg/kg | | Administration: | iv, once or twice a week for 4-13 weeks | | Result: | Reduced numbers of NK/B/T cells. |
| Animal Model: | Collagen-induced arthritis in cynomolgus monkey models[4] | | Dosage: | 3 mg/kg | | Administration: | iv,once weekly for 8 weeks | | Result: | Inhibited the progression of arthritis. |
| [References]
[1] Abadier M, et al. Mezagitamab induces immunomodulatory effect in patients with relapsed/refractory multiple myeloma (RRMM)[J]. Blood, 2020, 136: 9.
[2] Jadoon Y, et al. Immunotherapy in multiple myeloma. Cancer Treat Res Commun. 2021;29:100468. DOI:10.1016/j.ctarc.2021.100468
[3] Kuter DJ. Novel therapies for immune thrombocytopenia. Br J Haematol. 2022 Mar;196(6):1311-1328. DOI:10.1111/bjh.17872
[4] Roepcke S, et al., Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial. Pharmacol Res Perspect. 2018 Jun;6(3):e00402. DOI:10.1002/prp2.402
[5] Korver W, et al., A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys. J Pharmacol Exp Ther. 2019 Aug;370(2):182-196. DOI:10.1124/jpet.119.256602 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|